Relevant bibliographies by topics / Drug elution / Books
To see the other types of publications on this topic, follow the link: Drug elution.

Books on the topic 'Drug elution'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 21 books for your research on the topic 'Drug elution.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Krul, Kenneth G. Drug-eluting stents: Markets and technologies. Edited by Heffner Steven and Kalorama Information LLC. New York, N.Y: Kalorama Information, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

J, White Christopher, ed. Drug-eluting stents. London: Taylor & Francis, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

W, Serruys P., and Gershlick A. H, eds. Handbook of drug-eluting stents. London: Taylor & Francis, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Serruys, Patrick W., and Anthony H. Gershlick. Handbook of Drug-Eluting Stents. Informa Healthcare, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Serruys, Patrick W., and Anthony H. Gershlick. Handbook of Drug-Eluting Stents. CRC Press, 2005. http://dx.doi.org/10.1201/9780367800628.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

(Editor), Alexandre Abizaid, Martin B. Leon (Editor), and Alexandra Lansky (Editor), eds. Textbook of Drug Eluting Stents. Taylor & Francis Ltd, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

1967-, Mittmann Nicole, and Canadian Coordinating Office for Health Technology Assessment., eds. Drug eluting stents: An economic evaluation. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

1967-, Mittmann Nicole, and Canadian Coordinating Office for Health Technology Assessment., eds. Economic evaluation of drug eluting stents. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Antonio, Colombo, and Stankovic Goran MD, eds. Colombo's tips & tricks for drug-eluting stents. London: Taylor & Francis, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Colombo, Antonio, and Goran Stankovic. Colombo's Tips & Tricks for Drug Eluting Stents. Informa Healthcare, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

Colombo, Antonio, and Goran Stankovic. Colombo's Tips & Tricks for Drug Eluting Stents. CRC Press, 2005. http://dx.doi.org/10.3109/9780203024843.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Wu, Tim. Coronary Arterial Drug-Eluting Stent: From Structure to Clinical. INTECH Open Access Publisher, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Goraltchouk, Alex. Incorporation of drug-eluting microspheres into biodegradable nerve guidance channels for controlled drug delivery. 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

White, Christopher J. Drug-Eluting Stents: Advanced Applications for the Management of Coronary Disease. Informa Healthcare, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Huang, Yanming. Drug Eluting Stents: Anti-Inflammatory Approach To Prevent Restenosis After Stent Implantation (Acta Biomedica Lovaniensia). Leuven Univ Pr, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Farquhar-Smith, Paul. The additive analgesia of adrenaline in epidural blockade. Edited by Paul Farquhar-Smith, Pierre Beaulieu, and Sian Jagger. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198834359.003.0058.

Full text
Abstract:
The landmark paper discussed in this chapter is ‘Adrenaline markedly improves thoracic epidural analgesia produced by a low-dose infusion of bupivacaine, fentanyl and adrenaline after major surgery’, published by Niemi and Breivik in 1998. The analgesic potential of neuraxial blockade has long been recognized. The extensive opioid receptor expression in areas germane to pain pathways gave credence to the effective clinical application of lower doses of neuraxial opioids compared with systemic administration. Preclinical data also proposed a potential spinal action of α‎2 agonists in achieving analgesia by a number of mechanisms, including a direct antinociceptive action and by reducing elution of other epidural drugs from the spinal effector site. Early clinical data failed to show a clear benefit from the addition of adrenaline to epidural infusions. Niemi and Breivik’s experiment addressed the methodological flaws of previous studies by using combinations of relatively sub-analgesic doses of each of the combined elements.
APA, Harvard, Vancouver, ISO, and other styles
17

Coronary Stenting: A Companion to Topol's Textbook of Interventional Cardiology. Elsevier - Health Sciences Division, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

Kočka, Viktor, Steen Dalby Kristensen, William Wijns, Petr Toušek, and Petr Widimský. Percutaneous coronary interventions in acute coronary syndromes. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199687039.003.0047.

Full text
Abstract:
Three different guidelines of the European Society of Cardiology cover the field of percutaneous coronary interventions. Their main recommendations are the following:All patients with an ST-segment elevation myocardial infarction should undergo immediate coronary angiography and percutaneous coronary intervention as soon as possible after the first medical contact. Thrombolysis can be used as an alternative reperfusion therapy if the time delay to primary percutaneous coronary intervention is more than 2 hoursPatients with very high-risk non-ST-segment elevation acute coronary syndromes (recurrent or ongoing chest pain, profound or dynamic electrocardiogram changes, major arrhythmias, or haemodynamic instability) should undergo urgent coronary angiography within less than 2 hours after the initial hospital admissionAll moderate- to high-risk (GRACE score >140 or at least one primary high-risk criterion) non-ST-segment elevation acute coronary syndromes patients should undergo coronary angiography before discharge; the ideal timing is within 24 hours after admission for high-risk groups, and within 72 hours for moderate-risk groupsOther patients with recurrent symptoms or at least one high-risk criterion should undergo coronary angiography within 72 hours of first presentationLow-risk non-ST-segment elevation acute coronary syndromes may be treated conservatively, and the indication for an invasive evaluation can be done, based on the evidence of ischaemia during exercise stress testingStents should be used during all percutaneous coronary intervention procedures, whenever technically feasible. Second-generation drug-eluting stents do not increase stent thrombosis and can be safely used in the ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome settingsTriple pharmacotherapy, consisting of aspirin, thienopyridine antiplatelet agent, and anticoagulation with heparin or bivalirudin, should be used in all percutaneous coronary intervention procedures, with glycoprotein IIb/IIIa inhibitors added in patients with a high thrombus burden and low bleeding risk
APA, Harvard, Vancouver, ISO, and other styles
19

Kočka, Viktor, Steen Dalby Kristensen, William Wijns, Petr Toušek, and Petr Widimský. Percutaneous coronary interventions in acute coronary syndromes. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199687039.003.0047_update_001.

Full text
Abstract:
Three different guidelines of the European Society of Cardiology cover the field of percutaneous coronary interventions. Their main recommendations are the following:All patients with an ST-segment elevation myocardial infarction should undergo immediate coronary angiography and percutaneous coronary intervention as soon as possible after the first medical contact. Thrombolysis can be used as an alternative reperfusion therapy if the time delay to primary percutaneous coronary intervention is more than 2 hoursPatients with very high-risk non-ST-segment elevation acute coronary syndromes (recurrent or ongoing chest pain, profound or dynamic electrocardiogram changes, major arrhythmias, or haemodynamic instability) should undergo urgent coronary angiography within less than 2 hours after the initial hospital admissionAll moderate- to high-risk (GRACE score >140 or at least one primary high-risk criterion) non-ST-segment elevation acute coronary syndromes patients should undergo coronary angiography before discharge; the ideal timing is within 24 hours after admission for high-risk groups, and within 72 hours for moderate-risk groupsOther patients with recurrent symptoms or at least one high-risk criterion should undergo coronary angiography within 72 hours of first presentationLow-risk non-ST-segment elevation acute coronary syndromes may be treated conservatively, and the indication for an invasive evaluation can be done, based on the evidence of ischaemia during exercise stress testingStents should be used during all percutaneous coronary intervention procedures, whenever technically feasible. Second-generation drug-eluting stents do not increase stent thrombosis and can be safely used in the ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome settingsTriple pharmacotherapy, consisting of aspirin, thienopyridine antiplatelet agent, and anticoagulation with heparin or bivalirudin, should be used in all percutaneous coronary intervention procedures, with glycoprotein IIb/IIIa inhibitors added in patients with a high thrombus burden and low bleeding risk
APA, Harvard, Vancouver, ISO, and other styles
20

Kočka, Viktor, Steen Dalby Kristensen, William Wijns, Petr Toušek, and Petr Widimský. Percutaneous coronary interventions in acute coronary syndromes. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199687039.003.0047_update_002.

Full text
Abstract:
Three different guidelines of the European Society of Cardiology cover the field of percutaneous coronary interventions. Their main recommendations are the following: All patients with an ST-segment elevation myocardial infarction should undergo immediate coronary angiography and percutaneous coronary intervention as soon as possible after the first medical contact. Thrombolysis can be used as an alternative reperfusion therapy if the time delay to primary percutaneous coronary intervention is more than 2 hours. Patients with very high-risk non-ST-segment elevation acute coronary syndromes (recurrent or ongoing chest pain, profound or dynamic electrocardiogram changes, major arrhythmias, or haemodynamic instability) should undergo urgent coronary angiography within less than 2 hours after the initial hospital admissionAll moderate- to high-risk (GRACE score >140 or at least one primary high-risk criterion) non-ST-segment elevation acute coronary syndromes patients should undergo coronary angiography before discharge; the ideal timing is within 24 hours after admission for high-risk groups, and within 72 hours for moderate-risk groups. Other patients with recurrent symptoms or at least one high-risk criterion should undergo coronary angiography within 72 hours of first presentation. Low-risk non-ST-segment elevation acute coronary syndromes may be treated conservatively, and the indication for an invasive evaluation can be done, based on the evidence of ischaemia during exercise stress testing. Stents should be used during all percutaneous coronary intervention procedures, whenever technically feasible. Second-generation drug-eluting stents do not increase stent thrombosis and can be safely used in the ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome settings. Triple pharmacotherapy, consisting of aspirin, thienopyridine antiplatelet agent, and anticoagulation with heparin or bivalirudin, should be used in all percutaneous coronary intervention procedures, with glycoprotein IIb/IIIa inhibitors added in patients with a high thrombus burden and low bleeding risk.
APA, Harvard, Vancouver, ISO, and other styles
21

Kočka, Viktor, Steen Dalby Kristensen, William Wijns, Petr Toušek, and Petr Widimský. Percutaneous coronary interventions in acute coronary syndromes. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199687039.003.0047_update_003.

Full text
Abstract:
Three different guidelines of the European Society of Cardiology cover the field of percutaneous coronary interventions. Their main recommendations are the following: All patients with an ST-segment elevation myocardial infarction should undergo immediate coronary angiography and percutaneous coronary intervention as soon as possible after the first medical contact. Thrombolysis can be used as an alternative reperfusion therapy if the time delay to primary percutaneous coronary intervention is more than 2 hours. Patients with very high-risk non-ST-segment elevation acute coronary syndromes (recurrent or ongoing chest pain, profound or dynamic electrocardiogram changes, major arrhythmias, or haemodynamic instability) should undergo urgent coronary angiography within less than 2 hours after the initial hospital admissionAll moderate- to high-risk (GRACE score >140 or at least one primary high-risk criterion) non-ST-segment elevation acute coronary syndromes patients should undergo coronary angiography before discharge; the ideal timing is within 24 hours after admission for high-risk groups, and within 72 hours for moderate-risk groups. Other patients with recurrent symptoms or at least one high-risk criterion should undergo coronary angiography within 72 hours of first presentation. Low-risk non-ST-segment elevation acute coronary syndromes may be treated conservatively, and the indication for an invasive evaluation can be done, based on the evidence of ischaemia during exercise stress testing. Stents should be used during all percutaneous coronary intervention procedures, whenever technically feasible. Second-generation drug-eluting stents do not increase stent thrombosis and can be safely used in the ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome settings. Triple pharmacotherapy, consisting of aspirin, thienopyridine antiplatelet agent, and anticoagulation with heparin or bivalirudin, should be used in all percutaneous coronary intervention procedures, with glycoprotein IIb/IIIa inhibitors added in patients with a high thrombus burden and low bleeding risk.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Drug elution' for other source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography